Introduction to Datopotamab Deruxtecan EGFR-Mutated NSCLC On June 23, 2025, the FDA approved Datopotamab Deruxtecan EGFR-Mutated NSCLC treatment, known as…
Browsing: Oncology Research
The Matterhorn Trial, a landmark phase III study published in the New England Journal of Medicine, evaluates durvalumab, an anti-PD-L1…
At the 2025 ASCO Annual Meeting, new data on IO-based combinations in mRCC emerged. For instance, Dr. Brian Rini, MD…
Published: June 4, 2025Category: Lung Cancer Research Introduction to Neoadjuvant Nivolumab Plus Chemotherapy in CheckMate 816 The CheckMate 816 trial…
What’s New at ASCO 2025? The ASCO 2025 conference in Chicago brought exciting news for cancer care. A major study,…
ATOMIC Trial ASCO 2025: Key Results RevealedOn June 1, 2025, the ASCO Annual Meeting in Chicago presented the ATOMIC trial…
Introduction Cancer of Unknown Primary (CUP) diagnostics is a critical area for oncologists and researchers, as 2-5% of cancer cases…
OncologyTube.com presents the ASCO 2025 Top 10 Abstracts, highlighting practice-changing trials in oncology. It features advancements in cancer care, from…
The American Society of Clinical Oncology (ASCO) Annual Meeting is a pivotal event for oncology professionals, and ASCO 2025, happening…
Could 2025 Oncology Have Saved Steve Jobs from Pancreatic Cancer? A Deep Dive into Past and Future Treatments February 21,…